<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289406</url>
  </required_header>
  <id_info>
    <org_study_id>SK310_III_2006</org_study_id>
    <nct_id>NCT00289406</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension</brief_title>
  <official_title>An 8 Weeks, Multi-Center, Randomized, Double Blinded, Comparative Phase 3 Clinical Trial to Assess the Efficacy and Safety of S-Amlodipine Gentisate Compared to Amlodipine Besylate in Patients With Mild-to-Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      The goal of this study is to compare the antihypertensive effect and tolerability of
      S-amlodipine gentisate with those of amlodipine besylate in patients with mild to moderate
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date>February 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in mean changes from baseline in through sitting diastolic blood pressure after 8 weeks of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean changes in sitting systolic blood pressure; response rate (defined as the proportion of patients whose sDBP was ≤90mmHg or whose sDBP had decreased from baseline by ≥10 mmHg); changes in triglyceride and total cholesterol level of blood sample</measure>
  </secondary_outcome>
  <enrollment>110</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine gentisate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients are required to have a mean cuff sitting diastolic blood pressure of ≥90 and
             ≤109 mmHg after successful completion of the 2-week placebo run-in period

        Exclusion Criteria:

          -  any serious disorder that could limit the ability of the patient to participate in the
             study

          -  significant cardiovascular disease (angina, myocardial infarction, cerebrovascular
             disease, or significant arrhythmia in the preceding 6 months)

          -  uncontrolled diabetes mellitus (serum glucose level ≥140 mg/dl)

          -  insulin dependent diabetes mellitus (type I)

          -  secondary hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SK Chemicals Investigational Site Seoul, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SK Chemicals Investigational Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SKChemicals</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2006</study_first_submitted>
  <study_first_submitted_qc>February 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2006</study_first_posted>
  <last_update_submitted>March 5, 2007</last_update_submitted>
  <last_update_submitted_qc>March 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2007</last_update_posted>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

